and Thank you, everyone you Caroline, joining thank today. us for
ended across of quarter AVITA a execution our with quarter growth at March was The XXXX solid third here progress fiscal several of drivers.
into I may of I our Before to today be some listening new realize AVITA delve fairly you that Medical. performance, recent
quick prior with wound the regenerative a So the the the technology a onto known to company the patient's minutes I'll regenerate natural of as which to to a AVITA as or at Skin prepare use pigmentation. point commence healthy return XX skin, platform care can backgrounder with natural, medicine epidermis suspension, with moving Cells. Spray-On has to then progress. XX is commercial-stage And RECELL is Clinicians of the including of recent System, RECELL cellular skin. within System sprayed small sample which our a portrayed forward take proprietary commonly
providing patients, third degree RECELL to burns well-defined the second delivers System of large were commercial infection sizable payers. win-win that wounds created and compelling hospitals, the other treat required benefits dynamic to significantly scarring. Today, received PMA in efforts begin allowing parts RECELL XXXX, by Before to a clinical from of physicians, late painful donor their and potential burn skin reducing our pre-market which and grafts amount for approval bodies, sites or received provided skin us XXXX, and in extraordinarily patients and new secondary
is RECELL System standard applications what that confident burn not burns. of is estimate care RECELL in serviceable a limited increasingly rapidly are market, we $XXX the we and becoming million to as the While
As States injury skin abnormalities. have through stable we energized or involve their or variety defects opportunities. epidermis currently in who clinical treating seek previously our we our application patients remarkably disclosed, as who skin United that lost epidermis technology for specially prospective vitiligo, in patients common to have expansion approval a through our yet PMA leverage of to label progress three those These about to RECELL disorder. trials pivotal accident, in indications remain impaired of opportunity due undertreated or have a the We
the a of significant prospects, we're and to applications life-threatening disorders. number cell the gene pipeline within exploring therapy skin use arena or of clinical near-term RECELL our to for Beyond attend debilitating
I with that our background highlights turn quarter. now the will recent company, from some on to So
our both in many quarter fiscal of hampered by peers While business to revenues legacy progress with our have third were we demonstrate initiatives. our and our COVID-XX, pipeline the continued like burns
primarily compared XXXX, April. December to soft X% sales quarter which revenues of burns initial last the our down month to shutdown and Our COVID previous January, $X.X were the due lowest was since a million, to
of was As lower COVID as inventory well slight some during of as was quarter. to a to bought as XXX up fiscal in customers over experience stocking the January during a in combination overall their performance procedures rebate annual increase incidents slow due tiers. the a accident reminder, the performed second quarter, our RECELL part achieve We the Decembers did were a which quarter, improved factors, latter including
area, represent to concerted past in order accounts, or XX% penetration target efforts than to the in we've XX% XX months, burns burns TBSA admissions. body covering approximately burn less Over small established deepen of our made total surface
our in decreases six now total penetration, of the successful smaller increased burn RECELL with average the quarter, with I to cases hospital allows close our from see moving these with Consequently, also wounds. average of procedure many access this RECELL of new opened decreased. needle while the note access per consistent bringing should per the and plan. that XX% us XX. to which we the it this more System procedure, In revenue centers is to to come procedures, correspondingly we accounts, units been our have number third We number
are there States. United estimating, XXX ABA the centers in burn the With
We a on are feel established solid success team our market now this be utilization. and very driving commercial with will footprint in and we our that pleased focus we've
anticipate don't on regularly we looking such, this metric As updating ahead.
We using have also an seen increased of our new product. number surgeons
this perform this our are still the access cases as For example, the healthy support growth future We we Sales represents using approximately challenging. a into gain burn existing past indicator for XXX System, as surgeons. XXX as account most penetration in XX% and training. quarter, unique which accounts calls surgeons saw Today, we to to as view leading of RECELL able well to to drive we're base. U.S. aftercare
Furthermore Fiona center on honored heels However, the in Boswick presentations we Everett series our Wood of Lecture front at offsite with continued at Idris AVITA to small seeing where the Award, of Memorial successful community's are advanced and which practice use ongoing XXXX Care these post-market John observed American an to at the more A. North Evans RECELL was American Society meeting of at of the investigator-initiated and Memorial and XX Founder, demonstrates research RECELL. presentations Burn toward conferences events. in synergistic RECELL Symposium a Burns and the traction Association the important with the the commitment Burn products, Wound discussions shift with adoption topics and and integration strong meeting. be We
force on focusing will and As adding our our existing we be ahead, look surgeon primarily new expanding and users sales driving within usage accounts.
resume on purchasing third our stocking February in we quarter, saw working inventory mentioned March. were beginning of As we but last we the call, through at the and
limitations, in we impacts but signs May, are capacity of were due seeing and seeing also Here we reduced access improvement. still to
Moving progress in vitiligo our now to pipeline efforts. our
We have to the of XX level continue during the from seven to sites of vitiligo interest in study see a and number high increased our quarter.
approved being vitiligo vitiligo stable their meaning approximately with opportunity. spread. U.S. appear represents are market pigmented presents currently X.X sizeable XXX is the is including unresponsive to to of of opportunity there worldwide, is characterized autoimmune continuing condition, and are product is Vitiligo disease million approximately enable not million to billion autoimmune the RECELL. unfamiliar skin estimated as frontline underlying well-managed Americans. we a FDA us. the vitiligo presently attributed those X.X estimate available And in underlying The that market and for is an by no order disorder whose $X those treatments and million pigmentation as therapies, for stable market vitiligo repigmentation For a and in such Of to have U.S., topical that candidates patient. these white Patients approximately their for areas patients. suffers skin in are stable primarily the vitiligo a deep There an deep phototherapy patches
in Our tapping clinical trial into sites support population. require this
seen radio in situation, social a clinical recruitment outreach patients conventional particular these campaign, treatment, are To they on no routinely increases spending outreach many multimedia from and address in not we Given benefited that local longer April on enrollment. than setting. fiscal still when have launched expect radio, digital substantial at quarter including media. restrictions our in this a Rather media vaccinations recruitment in place, third campaigns see remained and initiated up were and ramping time these we to during subsequent the
of XXXX. vitiligo. to the study us months. months completion study, pivotal of three end to the Since subjects trial dropping fiscal uptick plan we an to our patients stable enrolled stability the of in System we enrolled required. In identified treat beginning we've disease in reducing the third the of in bringing the three and arm feasibility by already to thereby required have expect assessing our the for number participants patients RECELL are consider We use of XX, total total the pivotal coming approaching potential in referrals this have and enroll seen XX we an the study, and quarter, data, of another who to enrollment the potential points March, Early additional
half with FDA indication position believe we should the as early second usual market we as XXXX. in be timelines, enter U.S. to commercially to continue of Assuming calendar, the this review a
may thickness our have patient The goal BARDA third both burn XX contract You other to we our population. into XX Enrollment that pediatric the indication the expanding to include burns this funded quarter. partial study indications. during increased PMA ongoing, to label new trials pivotal the from by our two of study expand aims with recall in pediatric
communication pediatrics. analyses enrollment include from more in increase for necrotizing this of X we injuries, RECELLs continued trial access non-burn as FDA As of for such an trauma, programs prospective to this for alternative in potentially clinical degloving saw during soft data with involves stay compassionate wounds, Please soft a and XX. the an use we front. dialogue to engaged the tissue of and regarding to In support indication use potential collected infections our to tuned on reconstruction subjects which tissue are RECELL expansion prospective completion trial,
the patients and Colorado, off Houston the currently with Research the We programs Gates continue using for in through to with see in trial quarter aim on to for epidermolysis in paying calendar you are XX calendar see our enrolling in approximately year. like complete Work this With using RNA education. momentum. during efforts a in increased for walk for XX% XXX calendar To it physician trial has system. and and U.S. burn surgeons sites Medicine month University will Methodist surgeons engagements ahead. our both are this of EB, the proof-of-concept collaborations of we growth XXXX tissue we drive telomerase. to of we're drivers engagement our injury to six forward been an recruitment preliminary site for U.S. burn These Our year gratifying I'd the XX% trial. also in soft with follow-up the approval the to rejuvenation trained continues use RECELL now and progress this Institute for approximately to bullosa to XXXX. show begin, Center or Regenerative aiming plan
burn world-class We a have built physician base.
our further adding outreach engagement capabilities and programs training physician efforts. We and leveraging are new
soon. engaged and as example, look more our trainings reality we very virtual are we surgeons increase such dinners virtual offering launching in We're to programs, For to reality forward out remotely. an program rolling a and off-site adequately seeing
As we’ve access the all support, for been you cases as achieve all with challenging relaxing a bit, and access into restrictions able a March sales calls part, to however will improves. here we and aftercare remain update
team penetration our commercial to will be burn accounts. continuing Our drive center into
accounts. with a that and increase into a burns anticipate We recell smaller in in our penetration believe of driving shifting we focus the utilizing are centers. recell approved a broader usage critical in result these to I volume strategy and of ultimately the cases System. substantial will we mentioned, And mass are concentrate what burn As is of that, we on within back
Our of favorable are pivotal continue for less There a pursue completion. to registration moving clinical data COVID speedy toward three to make needed are and respect than vitiligo the pipeline and like, potential our in of vitiligo burn efforts existing changes the rebound reduction forward gains to trials from we'd despite a subjects indication. labeling with coming pediatric use the number of all
about continue preclinical We epidermolysis rejuvenation. work optimistic our bullosa to be in and pipeline
to year final for its made had We hoped services transitional early leverage XXXX. effect seeking a pilot last centers use which for CMS in to seek receive a Medicare expect XX. launch and Turning Medicare initiate of initial reimbursement, previously, as on TPT, heard outpatient experiencing when the our the specifically pass-through code, X C due additional recell on you've had the a or a Based its timeline, known in setting. delays in would setting. with application to will commercial we commence we with have for Medicaid and for the the a that January code communicated poised is those coverage System, that outpatient a to company CMS be to code of COVID C as by implemented and however, separate payers new the to team and or previously payment is payment sales is December support we C XXXX, outpatient to decision approach If
approval our Japan. growth last the partner, continue coming To we geographic in anticipate our that together footprint end to to COSMOTEC, seek we with Moving years. over our broadening, driver commercial
interactions COSMOTEC health and are and regulatory Japanese efforts authority actively Our with ongoing. the
remain across the Michael for Holder In broad and the thereby, the Michael? to summary, teeing details our frequently re-evaluating markets for genuinely the over U.S. sales growth. we in quarter. encouraged to x-U.S. up we call burn our our in of forces the ahead, prioritize re-entry to the believe our recell turn ability by utility despite and macro add to environment, looking we us market, platform financial CFO, we build indications demonstrated While clinical the procedural continue parallel, are in I'd like now account into we base center recell our as indications system. for performance challenging future on multiple new
